End-to-end peptide discovery platform
Therapeutic peptide discovery across topologies and non-canonical chemistry from hit identification to drug candidates
White paperMethods, datasets and limitationsCore capabilities
Orchestration across the whole peptide DMTA cycle
Where a programme enters
Selected stage
Evidence
Prospective first — programmes taken through synthesis and assay — then the retrospective benchmarks the methods rest on.
Programmes
Frequently asked questions
Start with the target
Tell us the target and where the programme stands. We will tell you what the platform can do with it, and what it cannot.
Discuss a programme
